Overview
Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center. He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology. He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009. He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer. He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World. He is very committed to training residents and mentoring students and trainees.
Office Hours
Clinic days: Tuesday and Thursday from 8am to 530pm
OR Days: 1st,3rd and 5th Mondays and selected Wednesdays and Fridays
Telehealth Clinics 2nd and 4h Mondays as selected other days
OR Days: 1st,3rd and 5th Mondays and selected Wednesdays and Fridays
Telehealth Clinics 2nd and 4h Mondays as selected other days
Current Duke Appointments & Affiliations
James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine
·
2009 - Present
Urology,
Clinical Science Departments
Professor of Urology
·
2005 - Present
Urology,
Clinical Science Departments
Professor in Anesthesiology
·
2012 - Present
Anesthesiology,
Clinical Science Departments
Member of the Duke Cancer Institute
·
2004 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Characterizing the Activity of Inflammasome-Related Genes and Their Association With Oncological Outcomes in Prostate Cancer.
Journal article Prostate · August 2026 BACKGROUND: Inflammation plays a critical role in cancer cell proliferation; however, the specific role of inflammasomes, multiprotein complexes that regulate inflammation-associated signaling pathways, in prostate cancer (PCa) remains insufficiently explo ... Full text Open Access Link to item CiteGenomic Prostate Score (GPS) as a Prognostic Biomarker in Patients With Localized Prostate Cancer Undergoing Focal Therapy.
Journal article Prostate · June 2026 BACKGROUND: Focal therapy (FT) encompasses ablation of the prostate cancer (PCa) while preserving the surrounding benign tissue, aiming to minimize or spare patients from postoperative complications. Although FT has been proven effective, the multifocal an ... Full text Link to item CiteIP62-16 PROGNOSTIC SIGNIFICANCE OF HSP90AB1 EXPRESSION IN PROSTATE CANCER: MOLECULAR ASSOCIATIONS AND CLINICAL IMPLICATIONS
Conference Journal of Urology · May 2026 Full text CiteRecent Grants
Phase III Randomized Efficacy and Safety Study
Clinical TrialPrincipal Investigator · Awarded by Medivation, Inc. · 2016 - 2027A Prospective Trial - Evaluation of ExoDx Prostate in Men with Prostate Cancer in an Active Surveillance Regimen
Clinical TrialPrincipal Investigator · Awarded by Exosome Diagnostics, Inc. · 2022 - 2026NWU22-12-01 A PHASE 2 PLACEBO-CONTROLLED TRIAL OF UROLITHIN A SUPPLEMENTATION IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY
ResearchCo Investigator · Awarded by Northwestern University · 2024 - 2025View All Grants
Education
Thomas Jefferson University ·
1982
M.D.
Pennsylvania State University ·
1979
B.S.